mTOR pathway as a potential target in a subset of human medulloblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian Target of Rapamycin (mTOR) pathway is crucial for protein synthesis and metabolism.
• Aberrant mTOR pathway activation is implicated in the development of various cancers, including medulloblastoma.

Purpose of the Study:

• To investigate the prognostic significance of the mTOR pathway in medulloblastoma.
• To evaluate the therapeutic potential of mTOR inhibitors as a treatment strategy for medulloblastoma.

Main Methods:

• Immunohistochemistry was used to assess phospho-mTOR (p-mTOR) and phospho-S6 (p-S6) expression in 40 medulloblastoma patient samples.
• Medulloblastoma cell lines (Daoy and UW228-2) were treated with mTOR inhibitors (rapamycin, NVP-BEZ235) alone and in combination with cytostatic drugs (cisplatin, etoposide).
• Expression of mTORC1 and mTORC2 components was analyzed in cell lines.

Main Results:

• p-mTOR and p-S6 expression did not correlate with patient age, gender, or histological subtype.
• Simultaneous expression of p-mTOR and p-S6 was observed in 22.5% of cases, with a trend towards inferior survival, though not statistically significant.
• UW228-2 cells exhibited higher sensitivity to mTOR inhibitors compared to Daoy cells.
• mTOR inhibitors significantly enhanced the antiproliferative effects of cytostatic drugs in both cell lines (p < 0.05).

Conclusions:

• The mTOR pathway's role in medulloblastoma prognosis requires further investigation with larger cohorts.
• mTOR inhibitors demonstrate potential as an adjunct therapy, significantly augmenting the efficacy of conventional cytostatic drugs in medulloblastoma cell lines.
• Targeting the mTOR pathway may offer a future therapeutic avenue for a specific subset of medulloblastoma patients.